Q3 EPS Estimates for Disc Medicine Lowered by HC Wainwright

Disc Medicine, Inc. (NASDAQ:IRON) – HC Wainwright reduced their Q3 2026 earnings per share estimates for Disc Medicine in a note issued to investors on Thursday, August 6th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($1.71) for the quarter, down from their prior estimate of ($1.70). HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($6.61) per share. HC Wainwright also issued estimates for Disc Medicine’s Q4 2026 earnings at ($1.74) EPS, FY2026 earnings at ($6.64) EPS, FY2027 earnings at ($6.47) EPS and FY2028 earnings at ($4.62) EPS.

Other analysts also recently issued research reports about the company. Wedbush reiterated an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a research report on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Morgan Stanley lifted their target price on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, June 15th. Finally, Wall Street Zen upgraded shares of Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $106.00.

Disc Medicine Price Performance

IRON opened at $78.28 on Monday. The stock’s 50 day simple moving average is $73.72 and its 200 day simple moving average is $69.81. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. Disc Medicine has a 1 year low of $40.00 and a 1 year high of $99.50. The firm has a market cap of $3.01 billion, a price-to-earnings ratio of -11.90 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17.

Institutional Trading of Disc Medicine

Several large investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Disc Medicine in the 2nd quarter worth approximately $180,502,000. RA Capital Management L.P. grew its stake in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock worth $156,925,000 after purchasing an additional 399,026 shares during the period. Vanguard Group Inc. grew its stake in Disc Medicine by 22.1% in the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after purchasing an additional 319,621 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Disc Medicine by 28.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock worth $134,839,000 after purchasing an additional 371,576 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Disc Medicine by 110.0% in the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after purchasing an additional 828,248 shares in the last quarter. 83.70% of the stock is owned by institutional investors.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 18,612 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $3,758,677.56. This represents a 25.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rahul Khara sold 7,500 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $70.22, for a total transaction of $526,650.00. Following the transaction, the insider owned 52,173 shares in the company, valued at $3,663,588.06. This represents a 12.57% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 110,712 shares of company stock valued at $7,997,536. 3.76% of the stock is currently owned by company insiders.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.